Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2022

Open Access 01-12-2022 | Colorectal Cancer | Research

CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule

Authors: Yuki Nakagami, Shoichi Hazama, Nobuaki Suzuki, Shin Yoshida, Shinobu Tomochika, Hiroto Matsui, Yoshitaro Shindo, Yukio Tokumitsu, Satoshi Matsukuma, Yusaku Watanabe, Michihisa Iida, Ryouichi Tsunedomi, Shigeru Takeda, Tomonobu Fujita, Yutaka Kawakami, Hiroyuki Ogihara, Yoshihiko Hamamoto, Tatsuya Ioka, Tsuyoshi Tanabe, Tomio Ueno, Hiroaki Nagano

Published in: BMC Cancer | Issue 1/2022

Login to get access

Abstract

Background

We recently reported the relapse-free survival (RFS) significance of the combination of CD4+ and forkhead box P3+ (FOXP3) T-cell densities identified by immunohistochemistry in patients with stage I, II, and III colorectal cancer (CRC) who underwent curative resections. This study was designed to determine the optimal combination of markers that predict recurrence in patients with T factors of T3/T4a stage II CRC by applying a novel Bayes decision rule.

Methods

Using 137 cancer tissue specimens from T3/T4a stage II patients, 12 clinicopathologic and immune factors were analysed as predictive candidates for recurrence.

Results

Our study showed that the combination of low CD4+ and low FOXP3+ T-cell densities resulted in extremely poor RFS.

Conclusions

Adjuvant chemotherapy may be considered for patients with a combination of low CD4+ and low FOXP3+ T-cell densities. The discovery of this new prognostic indicator is important for the appropriate management of patients undergoing curative resection for T3/T4a stage II CRC.
Appendix
Available only for authorised users
Literature
1.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMed
2.
3.
Brierley JD, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours: John Wiley & Sons. 2017.
4.
Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C. Towards the introduction of the ‘Immunoscore’in the classification of malignant tumours. J Pathol. 2014;232(2):199–209.CrossRef
5.
Sawayama H, Miyamoto Y, Hiyoshi Y, Ogawa K, Kato R, Akiyama T, Kiyozumi Y, Yoshida N, Baba H. Overall survival after recurrence in stage I-III colorectal cancer patients in accordance with the recurrence organ site and pattern. Ann Gastroenterol Surg. 2021;5(6):813–22.CrossRef
6.
Kobayashi H, Yamamoto H, Miyata H, Gotoh M, Kotake K, Sugihara K, Toh Y, Kakeji Y, Seto Y. Impact of adherence to board-certified surgeon systems and clinical practice guidelines on colon cancer surgical outcomes in Japan: A questionnaire survey of the National Clinical Database. Ann Gastroenterol Surg. 2020;4(3):283–93.CrossRef
7.
Dienstmann R, Salazar R, Tabernero J. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients. J Clin Oncol. 2015;33(16):1787–96.CrossRef
8.
Haller DG, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll H-J. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–71.CrossRef
9.
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–16.CrossRef
10.
Ueno H, Ishiguro M, Nakatani E, Ishikawa T, Uetake H, Matsuda C, Nakamoto Y, Kotake M, Kurachi K, Egawa T. Prospective multicenter study on the prognostic and predictive impact of tumor budding in stage II colon cancer: results from the SACURA trial. J Clin Oncol. 2019;37(22):1886.CrossRef
11.
Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19.CrossRef
12.
Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34.CrossRef
13.
Network NCC. NCCN Guidelines Colon Cancer (version 2.2015). 2015.
14.
Labianca R, Nordlinger B, Beretta G, Mosconi S, Mandalà M, Cervantes A, Arnold D. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24:vi64–72.CrossRef
15.
Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, Van de Velde C, Balmana J, Regula J. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Annals of oncology. 2012;23(10):2479–516.CrossRef
16.
Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2018;19(4):562–78.CrossRef
17.
You K, Park H-C, Park SC, Sohn DK, Oh JH, Lee D-W, Park S-S, Kang S-B, Heo SC, Kim MJ. Laparoscopic approach for T4 colon cancer can be associated with poor prognosis in right-sided T4b tumours. Euro J Surg Oncol. 2021;47(7):1645–50.
18.
Rottoli M, Stocchi L, Dietz DW. T4N0 colon cancer has oncologic outcomes comparable to stage III in a specialized center. Ann Surg Oncol. 2012;19(8):2500–5.CrossRef
19.
Pagès F, Mlecnik B, Marliot F, Bindea G, Ou F-S, Bifulco C, Lugli A, Zlobec I, Rau TT, Berger MD. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. The Lancet. 2018;391(10135):2128–39.CrossRef
20.
Kuwahara T, Hazama S, Suzuki N, Yoshida S, Tomochika S, Nakagami Y, Matsui H, Shindo Y, Kanekiyo S, Tokumitsu Y. Intratumoural-infiltrating CD4+ and FOXP3+ T cells as strong positive predictive markers for the prognosis of resectable colorectal cancer. Br J Cancer. 2019;121(8):659–65.CrossRef
21.
22.
Goto A, Nishikawa J, Hideura E, Ogawa R, Nagao M, Sasaki S, Kawasato R, Hashimoto S, Okamoto T, Ogihara H. Lymph node metastasis can be determined by just tumor depth and lymphovascular invasion in early gastric cancer patients after endoscopic submucosal dissection. Eur J Gastroenterol Hepatol. 2017;29(12):1346.CrossRef
23.
Jain AK, Dubes RC, Chen CC. Bootstrap techniques for error estimation. IEEE Trans Pattern Anal Mach Intell. 1987;9(5):628–33.CrossRef
24.
R Core Team: R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing 2019.
25.
Kinoshita T, Muramatsu R, Fujita T, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Kudo-Saito C. Prognostic value of tumor-infiltrating lymphocytes differs depending on histological type and smoking habit in completely resected non-small-cell lung cancer. Ann Oncol. 2016;27(11):2117–23.CrossRef
26.
McArdle P, Canna K, McMillan D, McNicol A, Campbell R, Underwood M. The relationship between T-lymphocyte subset infiltration and survival in patients with prostate cancer. Br J Cancer. 2004;91(3):541–3.CrossRef
27.
Bromwich E, McArdle P, Canna K, McMillan D, McNicol A, Brown M, Aitchison M. The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer. 2003;89(10):1906–8.CrossRef
28.
Droeser R, Zlobec I, Kilic E, Güth U, Heberer M, Spagnoli G, Oertli D, Tapia C. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer. 2012;12(1):1–10.CrossRef
29.
Huang Y, Liao H, Zhang Y, Yuan R, Wang F, Gao Y, Wang P, Du Z. Prognostic value of tumor-infiltrating FoxP3+ T cells in gastrointestinal cancers: a meta analysis. PLoS ONE. 2014;9(5): e94376.CrossRef
30.
Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186–92.CrossRef
31.
Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology. 2009;137(4):1270–9.CrossRef
32.
Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol. 2010;222(4):350–66.CrossRef
33.
Sakaguchi S. Naturally arising Foxp3-expressing CD25+ CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6(4):345–52.CrossRef
34.
Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 2014;27:1–7.CrossRef
35.
Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity. 2009;30(6):899–911.CrossRef
36.
Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490–500.CrossRef
37.
Group QC. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. The Lancet. 2007;370(9604):2020–9.CrossRef
38.
Labianca R, Marsoni S, Pancera G, Torri V, Zaniboni A, Erlichman C, Pater J, Shepherd L, Zee B, Seitz J. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. The Lancet. 1995;345(8955):939–44.CrossRef
39.
Gill S, Loprinzi CL, Sargent DJ, Thomé SD, Alberts SR, Haller DG, Benedetti J, Francini G, Shepherd LE, Francois Seitz J. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–806.CrossRef
40.
Figueredo A, Charette ML, Maroun J, Brouwers MC, Zuraw L. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 2004;22(16):3395–407.CrossRef
41.
Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20(19):3999–4005.CrossRef
42.
Kajiwara Y, Ishiguro M, Teramukai S, Matsuda C, Fujii S, Kinugasa Y, Nakamoto Y, Kotake M, Sakamoto Y, Kurachi K. A randomized phase III trial of 1-year adjuvant chemotherapy with oral tegafur-uracil (UFT) vs. surgery alone in stage II colon cancer: SACURA trial. In.: Am Soc Clinl Oncol. 2016.
43.
Ar B. Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004;22(16):3408–19.CrossRef
Metadata
Title
CD4 and FOXP3 as predictive markers for the recurrence of T3/T4a stage II colorectal cancer: applying a novel discrete Bayes decision rule
Authors
Yuki Nakagami
Shoichi Hazama
Nobuaki Suzuki
Shin Yoshida
Shinobu Tomochika
Hiroto Matsui
Yoshitaro Shindo
Yukio Tokumitsu
Satoshi Matsukuma
Yusaku Watanabe
Michihisa Iida
Ryouichi Tsunedomi
Shigeru Takeda
Tomonobu Fujita
Yutaka Kawakami
Hiroyuki Ogihara
Yoshihiko Hamamoto
Tatsuya Ioka
Tsuyoshi Tanabe
Tomio Ueno
Hiroaki Nagano
Publication date
01-12-2022
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2022
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-022-10181-7

Other articles of this Issue 1/2022

BMC Cancer 1/2022 Go to the issue

Research

Carboplatin dose calculations for patients with lung cancer: significant dose differences found depending on dosing equation choice

Research article

Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial

Research

Higher thymocyte selection-associated high mobility group box (TOX) expression predicts poor prognosis in patients with ovarian cancer

Research

Postoperative survival effect of the number of examined lymph nodes on esophageal squamous cell carcinoma with pathological stage T1–3N0M0

Study protocol

ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial

Research

The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits